This is a summary of the European public assessment report (EPAR) for Insulin lispro Sanofi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Insulin lispro Sanofi. For practical information about using Insulin lispro Sanofi, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Insulin lispro Sanofi is also indicated for the initial stabilisation of diabetes mellitus.
Therapeutic Area (MeSH)
N/AATC Code
A10AB04
ATC Item
insulin lispro
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| insulin lispro | N/A | 重组赖脯胰岛素 |
EMA Name
Insulin lispro Sanofi
Medicine Name
Insulin lispro Sanofi
Aliases
N/ANo risk management plan link.
